(This is associative evidence and may reflect confounding by indication, surveillance patterns, and glycaemic differences.) For post-marketing pharmacovigilance, FAERS-based analyses of semaglutide identify multiple safety signals (e.g., gastrointestinal obstruction-related terms, dehydration/volume depletion in some GLP-1RA analyses), but vulvovaginal dryness/infection/discharge/pain are not prominent as labelled risks in the major semaglutide FAERS disproportionality paper retrieved here
The Hidden Long-Term Effects of GLP-1 Medications: What You Need to Know For millions struggling with weight management and type 2 diabetes, GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have emerged as game-changing medications
[1] Additionally, notify your prescriber if you are pregnant, planning pregnancy, or breastfeeding, as tirzepatide is not recommended during pregnancy
For GLP-1s for overweight adults, the FDA label says they should have at least one additional, unspecified health risk